Back to results
US 2024/0262803 A1Published application
Compounds, compositions and methods of treating disorders
OwnerDun Yang, Jing Zhang +6inventors
InventorsDun Yang, Jing Zhang, Shenqiu Zhang, Thaddeus Allen, Qiong Shi, Gang Lv, Hongmei Li, Chenglu Yang
Life of this patent
Estimating the term…
Abstract
The present disclose includes, among other things, compounds that treat or lessen the severity of cancer, pharmaceutical compositions and methods of making and using the same.
Claims20
A compound of formula I:
- or a pharmaceutically acceptable salt,
- wherein
- X is —CH═ or —N═;
- Group A is optionally substituted phenyl or optionally substituted 6-membered heteroaryl;
- each Ra is independently selected from the group consisting of halogen, —CN, —OH, —OR1, —SR1, —NH2, —NR2R3, —C(O)R1, —C(O)OH, —C(O)OR1, —C(O)NH2, —C(O)NR2R3, optionally substituted C1-C7 aliphatic, optionally substituted phenyl, optionally substituted 5-10 membered heteroaryl, and optionally substituted 5-10 membered heterocyclyl;
- Rc1 is selected from the group consisting of C1-C6 haloalkyl, halogen, —OR1, —C(O)OR1, and optionally substituted 5-6 membered heteroaryl;
- Rc2 is selected from the group consisting of halogen, —CN, —OH, —OR1, —NH2, —NR2R3 optionally substituted C1-C7 aliphatic, optionally substituted phenyl, —C(O)R1, —C(O)OH, —C(O)OR1, —C(O)NH2, —C(O)NR2R3, optionally substituted 5-10 membered heteroaryl, and optionally substituted 5-10 membered heterocyclyl;
- each R1 is independently selected from the group consisting of optionally substituted C1-C6 aliphatic, optionally substituted phenyl, optionally substituted 5-10 membered heteroaryl, and optionally substituted 5-10 membered heterocyclyl;
- each R2 is independently selected from the group consisting of —C(O)R1, —C(O)OR1, —C(O)NR1R3, optionally substituted C1-C6 aliphatic, optionally substituted phenyl, optionally substituted 5-10 membered heteroaryl, and optionally substituted 5-10 membered heterocyclyl;
- each R3 is independently selected from the group consisting of hydrogen, —C(O)R′, —C(O)OR1, —C(O)NHR1, optionally substituted C1-C6 aliphatic, optionally substituted phenyl, optionally substituted 5-10 membered heteroaryl, and optionally substituted 5-10 membered heterocyclyl;
- and
- m is 0, 1, 2, 3, 4, or 5.
9 more elements
A compound selected from the group consisting of
- NO.
- Structure
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 17
- 18
- 19
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 50
- 52
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- or a pharmaceutically acceptable salt thereof.
80 more elements
A pharmaceutical composition comprising a compound of any of the previous claims and a pharmaceutically acceptable excipient.
A compound of formula II:
- or a pharmaceutically acceptable salt,
- wherein
- Rc1 is selected from the group consisting of C1-C6 haloalkyl, —OR1, —C(O)OR1, and optionally substituted 5-6 membered heteroaryl;
- Rx is selected from the group consisting of halogen, —CN, —OH, —OR1, —NH2, —NR2R3, optionally substituted C1-C7 aliphatic, optionally substituted phenyl, —C(O)R1, —C(O)OH, —C(O)OR1, —C(O)NH2, —C(O)NR2R3, optionally substituted 5-10 membered heteroaryl, and optionally substituted 5-10 membered heterocyclyl;
- and
- k is 0, 1, 2, or 3.
3 more elements
A compound represented by:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.